LYFGENIA is a one-time gene therapy to treat sickle cell disease in individuals 12 years of age or older and a history of vaso-occlusive events (VOEs). About LYFGENIA · Learn how LYFGENIA works · Steps to Treatment · FAQs

LYFGENIA is a gene addition therapy designed to add genetic material to your cells through a viral vector. Learn how LYFGENIA works at the genetic level.

Lovotibeglogene autotemcel, sold under the brand name Lyfgenia, is a lentiviral gene therapy used for the treatment of sickle cell disease.

10 июл. 2024 г. · LYFGENIA is indicated for treatment of patients 12 years of age or older with sickle cell disease and a history of vaso-occlusive events ...

LYFGENIA is a one-time gene therapy for people 12 years and older with sickle cell disease and a history of vaso-occlusive events.

4 янв. 2024 г. · Lyfgenia (lovotibeglogene autotemcel) is a gene therapy that is given as a one-time intravenous suspension to treat adults and children aged ...

LYFGENIA is a one-time gene therapy treatment for people age 12 years or older with sickle cell disease and a history of vaso-occlusive pain crises.

LYFGENIA adds functional copies of a modified form of the β-globin gene (βA-T87Q-globin gene) through gene addition.

LYFGENIA is indicated for the treatment of patients 12 years of age or older with sickle cell disease and a history of vaso-occlusive events. Limitations of Use.

8 дек. 2023 г. · LYFGENIA is a one-time ex-vivo lentiviral vector gene therapy approved for the treatment of patients 12 years of age or older with sickle cell ...